Chair and Department of Medical Microbiology, Medical University of Lublin, Lublin, Poland.
Pol J Microbiol. 2021 Mar;70(1):25-32. doi: 10.33073/pjm-2021-013. Epub 2021 Feb 24.
Chronic respiratory diseases account for high morbidity and mortality, with asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) being the most prevalent globally. Even though the diseases increase in prevalence, the exact underlying mechanisms have still not been fully understood. Despite their differences in nature, pathophysiologies, and clinical phenotypes, a growing body of evidence indicates that the presence of lung microbiota can shape the pathogenic processes underlying chronic inflammation, typically observed in the course of the diseases. Therefore, the characterization of the lung microbiota may shed new light on the pathogenesis of these diseases. Specifically, in chronic respiratory tract diseases, the human microbiota may contribute to the disease's development and severity. The present review explores the role of the microbiota in the area of chronic pulmonary diseases, especially COPD, asthma, and CF.
慢性呼吸系统疾病发病率和死亡率高，其中哮喘、慢性阻塞性肺疾病（COPD）和囊性纤维化（CF）在全球最为普遍。尽管这些疾病的发病率在增加，但确切的潜在机制仍未完全了解。尽管它们在性质、病理生理学和临床表型上存在差异，但越来越多的证据表明，肺部微生物组的存在可以影响慢性炎症的发病过程，而慢性炎症通常在这些疾病的病程中观察到。因此，对肺部微生物组的特征分析可能为这些疾病的发病机制提供新的认识。具体来说，在慢性呼吸道疾病中，人类微生物组可能有助于疾病的发展和严重程度。本综述探讨了微生物组在慢性肺部疾病（尤其是 COPD、哮喘和 CF）领域中的作用。
